sur Heidelberg Pharma AG (isin : DE000A11QVV0)
Heidelberg Pharma Reports 2024 Financial Results and Clinical Progress
Heidelberg Pharma AG has released its financial figures for 2024, highlighting significant milestones. Notably, one patient in the HDP-101 clinical trial for multiple myeloma achieved complete remission. This underlines the potential of Heidelberg's ADC technology as a cancer therapy. Additionally, HDP-102 trials targeting non-Hodgkin lymphoma are set to commence.
Financially, the company saw improved results, driven by a USD 20 million payment from HealthCare Royalty, extending their cash runway. Despite a decrease in annual revenues to EUR 12.0 million from EUR 16.8 million, operating expenses fell significantly.
Looking forward, the firm anticipates income between EUR 9.0 million and EUR 11.0 million for 2025, with continued investment in key projects facilitated by strategic financial agreements.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Heidelberg Pharma AG